Thomas Pataillot-Meakin
Research Subjects
Thomas Pataillot-Meakin has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Lynne Bevan
Imperial College London, London, UK
2 shared publications Akifumi Shibakawa
Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK
1 shared publication- Aleksandar P. Ivanov
Department of Chemistry, Imperial College London, London, UK
1 shared publication - Alice Piapi
UCL Cancer Institute, London, United Kingdom
1 shared publication Alice Vitali
Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK
1 shared publicationArtemis Gavriil
Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK
1 shared publication
Latest Publications
- Open Access
- 14 November 2022
- Published by Elsevier in Cytotherapy
- Vol. 25 (1) , 46-58
Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells
- 14 November 2022
- Published by Elsevier in Cytotherapy
- Vol. 25 (1) , 46-58
Open AccessTargeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells
- Open Access
- 11 November 2022
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 7 (11) , 3389-3398
Detection of YAP1 and AR-V7 mRNA for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform
Prostate cancer (PCa) is the second most common cause of male cancer-related death worldwide. The gold standard of treatment for advanced PCa is androgen deprivation therapy (ADT). However, eventual failure of ADT is common and leads to lethal metastatic castration-resistant PCa. As such, the detection of relevant biomarkers in the blood for drug resistance in metastatic castration-resistant PCa patients could lead to personalized treatment options. mRNA detection is often limited by the low specificity of qPCR assays which are restricted to specialized laboratories. Here, we present a novel reverse-transcription loop-mediated isothermal amplification assay and have demonstrated its capability for sensitive detection of AR-V7 and YAP1 RNA (3 × 101 RNA copies per reaction). This work presents a foundation for the detection of circulating mRNA in PCa on a non-invasive lab-on-chip device for use at the point-of-care. This technique was implemented onto a lab-on-chip platform integrating an array of chemical sensors (ion-sensitive field-effect transistors) for real-time detection of RNA. Detection of RNA presence was achieved through the translation of chemical signals into electrical readouts. Validation of this technique was conducted with rapid detection (<15 min) of extracted RNA from prostate cancer cell lines 22Rv1s and DU145s.
- 11 November 2022
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 7 (11) , 3389-3398
Open AccessDetection of YAP1 and AR-V7 mRNA for Prostate Cancer Prognosis Using an ISFET Lab-On-Chip Platform
Prostate cancer (PCa) is the second most common cause of male cancer-related death worldwide. The gold standard of treatment for advanced PCa is androgen deprivation therapy (ADT). However, eventual failure of ADT is common and leads to lethal metastatic castration-resistant PCa. As such, the detection of relevant biomarkers in the blood for drug resistance in metastatic castration-resistant PCa patients could lead to personalized treatment options. mRNA detection is often limited by the low specificity of qPCR assays which are restricted to specialized laboratories. Here, we present a novel reverse-transcription loop-mediated isothermal amplification assay and have demonstrated its capability for sensitive detection of AR-V7 and YAP1 RNA (3 × 101 RNA copies per reaction). This work presents a foundation for the detection of circulating mRNA in PCa on a non-invasive lab-on-chip device for use at the point-of-care. This technique was implemented onto a lab-on-chip platform integrating an array of chemical sensors (ion-sensitive field-effect transistors) for real-time detection of RNA. Detection of RNA presence was achieved through the translation of chemical signals into electrical readouts. Validation of this technique was conducted with rapid detection (<15 min) of extracted RNA from prostate cancer cell lines 22Rv1s and DU145s.
- Top Cited PapersOpen Access
- 10 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Single-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum
MicroRNAs (miRNAs) play essential roles in post-transcriptional gene expression and are also found freely circulating in bodily fluids such as blood. Dysregulated miRNA signatures have been associated with many diseases including cancer, and miRNA profiling from liquid biopsies offers a promising strategy for cancer diagnosis, prognosis and monitoring. Here, we develop size-encoded molecular probes that can be used for simultaneous electro-optical nanopore sensing of miRNAs, allowing for ultrasensitive, sequence-specific and multiplexed detection directly in unprocessed human serum, in sample volumes as small as 0.1 μl. We show that this approach allows for femtomolar sensitivity and single-base mismatch selectivity. We demonstrate the ability to simultaneously monitor miRNAs (miR-141-3p and miR-375-3p) from prostate cancer patients with active disease and in remission. This technology can pave the way for next generation of minimally invasive diagnostic and companion diagnostic tests for cancer.
- 10 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Top Cited PapersOpen AccessSingle-molecule amplification-free multiplexed detection of circulating microRNA cancer biomarkers from serum
MicroRNAs (miRNAs) play essential roles in post-transcriptional gene expression and are also found freely circulating in bodily fluids such as blood. Dysregulated miRNA signatures have been associated with many diseases including cancer, and miRNA profiling from liquid biopsies offers a promising strategy for cancer diagnosis, prognosis and monitoring. Here, we develop size-encoded molecular probes that can be used for simultaneous electro-optical nanopore sensing of miRNAs, allowing for ultrasensitive, sequence-specific and multiplexed detection directly in unprocessed human serum, in sample volumes as small as 0.1 μl. We show that this approach allows for femtomolar sensitivity and single-base mismatch selectivity. We demonstrate the ability to simultaneously monitor miRNAs (miR-141-3p and miR-375-3p) from prostate cancer patients with active disease and in remission. This technology can pave the way for next generation of minimally invasive diagnostic and companion diagnostic tests for cancer.
- 1 April 2016
- Published by Taylor & Francis in Epigenomics
- Vol. 8 (4) , 451-454
3-Methylcytosine in Cancer: An Underappreciated Methyl Lesion?
- 1 April 2016
- Published by Taylor & Francis in Epigenomics
- Vol. 8 (4) , 451-454
3-Methylcytosine in Cancer: An Underappreciated Methyl Lesion?